Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction

医学 射血分数 螺内酯 心力衰竭 内科学 心脏病学 分数(化学) 化学 有机化学
作者
Scott D. Solomon,Brian Claggett,Eldrin F. Lewis,Akshay S. Desai,Inder S. Anand,Nancy K. Sweitzer,Eileen O’Meara,Sanjiv J. Shah,Sonja M. McKinlay,Jerome L. Fleg,George Sopko,Bertram Pitt,Marc A. Pfeffer
出处
期刊:European Heart Journal [Oxford University Press]
卷期号:37 (5): 455-462 被引量:531
标识
DOI:10.1093/eurheartj/ehv464
摘要

AIMS: While mineralocorticoid receptor antagonists (MRAs) have been shown to benefit patients with reduced left ventricular ejection fraction (LVEF), spironolactone did not reduce the primary endpoint of cardiovascular death, heart failure hospitalization, or aborted cardiac arrest in patients with heart failure with preserved ejection fraction (HFpEF) in the TOPCAT trial, which enrolled patients with LVEF of 45% or greater. We utilized data from TOPCAT to assess the relationship between LVEF as well as outcomes and efficacy of spironolactone. METHODS AND RESULTS: We assessed differences in baseline characteristics and outcomes across LVEF categories in 3444 patients with HFpEF, and determined whether LVEF modified the treatment effect of spironolactone. Ejection fraction ranged from 44 to 85%. Patients with higher ejection fraction were older, more likely to be female, less likely to have a history of myocardial infarction, and more likely to have a history of hypertension and diabetes. The incidence of the primary endpoint and cardiovascular death was highest in patients at the lower end of the ejection fraction spectrum. Ejection fraction modified the spironolactone treatment effect, particularly in the patients enrolled in the Americas, for the primary outcome (P = 0.046) and for heart failure hospitalization (P = 0.039), with stronger estimated benefits of spironolactone at the lower end of the ejection fraction spectrum with respect to the primary endpoint (LVEF <50%: HR 0.72, 95% CI 0.50, 1.05; LVEF ≥60%: HR 0.97, 95% CI 0.76, 1.23) and heart failure hospitalization (LVEF <50%: HR 0.76, 95% CI 0.46, 1.27; LVEF ≥60%: HR 0.98, 95% CI 0.74, 1.30). CONCLUSION: In patients with HFpEF enrolled in TOPCAT, patient characteristics and outcomes varied substantially by LVEF. The potential efficacy of spironolactone was greatest at the lower end of the LVEF spectrum. CLINICALTRIALSGOV NUMBER: NCT00094302.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Marksman497发布了新的文献求助10
1秒前
不学无术的学术完成签到,获得积分10
3秒前
DavidXu完成签到,获得积分10
3秒前
Jerry完成签到 ,获得积分10
3秒前
牧青应助Sailing采纳,获得200
3秒前
跳跃的滑板完成签到,获得积分10
5秒前
shouren完成签到,获得积分10
5秒前
5秒前
5秒前
6秒前
晴天完成签到,获得积分10
6秒前
高高菠萝完成签到 ,获得积分10
7秒前
8秒前
Marksman497发布了新的文献求助10
8秒前
8秒前
田様应助Lily采纳,获得10
8秒前
明亮白筠完成签到,获得积分10
8秒前
10秒前
10秒前
Sleep_tight完成签到,获得积分10
11秒前
12秒前
许ZY完成签到,获得积分10
12秒前
是谁还没睡完成签到 ,获得积分10
12秒前
SciGPT应助风趣的灵枫采纳,获得10
12秒前
不会画画发布了新的文献求助10
13秒前
乐瑶完成签到,获得积分20
14秒前
丘比特应助谨慎的绿真采纳,获得10
14秒前
14秒前
Marksman497发布了新的文献求助10
14秒前
phdsyma发布了新的文献求助20
14秒前
斯文败类应助emberlynn采纳,获得20
15秒前
15秒前
17秒前
Marksman497发布了新的文献求助10
17秒前
老实的清炎完成签到,获得积分10
17秒前
18秒前
Literaturecome完成签到,获得积分10
18秒前
18秒前
高大的千秋完成签到,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Navigating Normative Orders. Interdisciplinary Perspectives 800
Organizational Behavior 510
Management and the Arts 510
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
CLSI VET01S-2024 Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals (7th Ed) 500
A Case Study on Hotels as Noncongregate Emergency Living Accommodations for Returning Citizens 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7755824
求助须知:如何正确求助?哪些是违规求助? 9302323
关于积分的说明 20268682
捐赠科研通 7338822
什么是DOI,文献DOI怎么找? 3311313
关于科研通互助平台的介绍 2462344
邀请新用户注册赠送积分活动 2324713